绥美凯详细的说明书

Since it is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai, which is launched in India. Suimeikai, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices. What we want to know today is Suimeikai’s detailed instructions.

Generic name: Doptabalamid tablets

Product name: Suimeikai

All names: Suimeike, Dotiabalamid tablets, TRIUMEQ, Inbec

Suimeikai Indications: Suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). 

Usage and Dosage of Suimeikan Adults and adolescents (weighing at least 40kg). For adults and adolescents, the recommended dosage of Suimeikan is one tablet, once a day. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. 

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

  Adverse reactions of Trimax: Clinical data on Trimax are limited. The most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%). 

Adverse reactions (nausea, vomiting, diarrhea, pyrexia, drowsiness, rash) occur frequently in patients with abacavir hypersensitivity reactions. Therefore, patients who develop these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be discontinued. 

In individual patients, the most serious adverse events that may be associated with dolutegravir and abacavir/lamivudine are hypersensitivity reactions, including rash and severe hepatic effects. An analysis of pooled data from Phase IIb to IIIb clinical trials found that the adverse reactions observed with the combination of dolutegravir + abacavir/lamivudine were generally consistent with the adverse reaction profiles of the single ingredients dolutegravir, abacavir, and lamivudine. There was no difference in the severity of adverse reactions observed between the combination and the single ingredients. 

The above is the content of the manual, I hope it can help you!